GOVX GeoVax Corp: רווח נקי למניה ב-12 החודשים האחרונים

GeoVax Labs, Inc. (GOVX) develops vaccines against cancer and infections for government contracts. While geopolitics and biological weapon threats fuel short-term demand, long-term success relies on the GV-MVA-VLP platform. The EPS YoY TTM percentage trend captures this balance, where the parameter value reaches -448.60. However, a high dependence on grants and narrow specialization create significant binary risks for capital.
GeoVax Corp - פילוחים אנליטיים ומדדי מפתח (GOVX)

Investors utilize earnings multiples to verify business sustainability and assess the quality of the issuer's capitalization. By analyzing the EPS YoY TTM growth efficiency metric, you evaluate the net income per share dynamics over a rolling year, which for GeoVax Labs, Inc. (GOVX) reflects the financial results derived from the stable operation of sterile laboratories and the uninterrupted production of vaccine candidates.